Can Sjögren's (Sjögren's syndrome) syndrome cause a decrease in Diffusing Capacity of the Lung for Carbon Monoxide (DLCO)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: January 27, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Can Sjögren's Syndrome Cause Decreased DLCO?

Yes, Sjögren's syndrome commonly causes decreased DLCO, with reduction occurring in up to 81.8% of patients, making it one of the most frequent pulmonary function abnormalities in this disease. 1

Prevalence and Significance of DLCO Reduction

  • DLCO reduction is the predominant pulmonary function abnormality in Sjögren's syndrome, occurring even when spirometry remains normal. 2
  • Research demonstrates that 81.8% of primary Sjögren's syndrome patients show reduced DLCO, with 45.5% having mild deficits and 36% having moderate deficits. 2
  • The reduction in DLCO often represents early emphysematous changes or interstitial lung disease (ILD) before spirometric abnormalities or significant respiratory symptoms develop. 2

Disease Severity Stratification Using DLCO

The 2021 Chest consensus guidelines establish DLCO as a critical parameter for staging Sjögren's-ILD severity: 1

  • Moderate disease activity: DLCO between 40% and 70% predicted
  • Severe/high disease activity: DLCO < 40% predicted

Mechanisms of DLCO Reduction

DLCO reduction in Sjögren's syndrome results from multiple pulmonary manifestations: 2, 3

  • Interstitial lung disease (ILD) occurs in 9-30% of patients and is the primary cause of DLCO reduction, with nonspecific interstitial pneumonia being the most common pattern. 1, 3
  • Emphysematous changes are found in up to 94.5% of patients and may represent early pulmonary involvement even before ILD becomes apparent. 2
  • Diffuse lymphocytic infiltration of airways and small airways disease contribute to gas exchange abnormalities. 3

Clinical Implications and Monitoring

Baseline DLCO measurement is mandatory for all Sjögren's patients with suspected or established ILD, with initial follow-up testing every 3-6 months for at least 1-2 years. 1

  • DLCO correlates with disease severity and mortality risk in Sjögren's-ILD patients. 4, 5
  • Patients with extraglandular Sjögren's syndrome show significantly lower DLCO compared to controls and even compared to scleroderma patients. 4
  • DLCO impairment correlates with the presence of cryoglobulins and low complement levels, suggesting immune complex deposition as a mechanism. 4

Important Clinical Pitfalls

  • Discordance between PFT abnormalities, symptoms, and HRCT findings commonly occurs in Sjögren's syndrome, so DLCO reduction may be present despite minimal symptoms or normal chest imaging. 1
  • DLCO reduction can occur with normal spirometry in 95.4% of patients, making it a more sensitive marker than dynamic lung volumes for early pulmonary involvement. 2
  • The presence of reduced DLCO should prompt HRCT evaluation to characterize the pattern of lung involvement and guide treatment decisions. 1

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Pulmonary manifestations of Sjögren's syndrome.

European respiratory review : an official journal of the European Respiratory Society, 2016

Research

Respiratory involvement in patients with Sjögren's syndrome: is it a problem?

Scandinavian journal of rheumatology. Supplement, 1986

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.